Exciting News: myriamed GmbH's Arne Östlind is attending the health.tech conference in munich from 05-06.2024

myriamed Gmb's ultimate aim is to contribute to the development of new cures for today‘s most debilitating diseases by defining wanted and unwanted drug effects at the earliest possible time point.

With 20+ years of experience in cell and engineered muscle models we are determined to provide our customers with standardized and individualized solutions to move preclinical drug development closer to clinical reality.

myriamed GmbH's wholly human platforms allow for detailed mode of action analyses and a rationale dosing strategy for early clinical trials. This is particularly useful in cases where animal models largely fail, i.e., in the development of new therapies targeting specific human molecules (protein, RNA, DNA).

Want to meat Arne Östlind in person and talk about the myriamed GmbH approach?

Just use the health tech app: https://lnkd.in/dz-wqwHr or contact us via the myriamed GmbH website.

More about the health.tech conference: https://www.health.tech